Overview

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Status:
Active, not recruiting
Trial end date:
2023-05-18
Target enrollment:
Participant gender:
Summary
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie